Come up with a name for your new list and we'll add to it:
Agensys raised a round of funding on October 15, 1999. Investors include
LODH Private Equity Partners.
Agensys, Inc. is developing a pipeline of therapeutic fully human monoclonal antibodies (MAbs) to treat solid tumor cancers based on its own proprietary targets. The Company has discovered and validat…